구조모아 (StructureMoa)항암 chemical structure spider web
방문Liaoning Medical DiagnosisTreatment Technology ResearchDevelopment Co.Ltd.
Autologous immune Cells(Liaoning Medical Diagnosis and Treatment Technology Research and Development Co., Ltd.)은 Lung Cancer (Locally Advanced or Metasta 표적 세포·유전자 치료로, Lung Cancer (Locally Advanced or Metastatic); Liver Cancer (Locally Advanced or Metastatic) 영역에서 개발·상용화 중입니다. 작용기전: checkpoint co-expression score correlated with both overall and contact-dependent tumor cell death. Phase 2에서 효능·안전성 신호를 검증 중입니다. OS: 16. 차별점: novel treatment approach aiming to increase precision and reduce toxicity compared with traditional immune checkpoint inhibit.
구조화 카탈로그 레코드입니다. Curated Core만큼 깊게 검토되지 않았습니다.
구조화 데이터
Lung Cancer (Locally Advanced or Metasta
Lung Cancer (Locally Advanced or Metastatic); Liver Cancer (Locally Advanced or Metastatic)
Recruiting
2026-07-13
Data Confidence · Medium
Development Signal · Emerging
NK cell activation in MDOTS when combined with TGFβ and PD-1
Lentiviral vectors encoding murine or human IL6/1 were designed using Vector Builder and e
novel treatment approach aiming to increase precision and reduce toxicity compared with traditional immune checkpoint inhibit
checkpoint co-expression score correlated with both overall and contact-dependent tumor cell death
T-cell activation
apoptosis through soluble inflammatory mediators in a same-donor primary-cell system
biomarkers and therapeutic targets for investigating tumor-specific immune responses following locoregional t
downregulation of inflammation-related pathways, whereas another allogeneic donor strain induced a distinct transcriptional profile
구조화 데이터
rates anti-tumor activity in human melanoma xenograft
mouse
PD
구조화 데이터
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.
바이오정보모아는 연구·교육용 과학·의약품 개발 정보입니다. 진료, 진단, 치료 지침, 규제 자문이 아닙니다.
Liaoning Medical DiagnosisTreatment Technology ResearchDevelopment Co.Ltd.
Autologous immune Cells(Liaoning Medical Diagnosis and Treatment Technology Research and Development Co., Ltd.)은 Lung Cancer (Locally Advanced or Metasta 표적 세포·유전자 치료로, Lung Cancer (Locally Advanced or Metastatic); Liver Cancer (Locally Advanced or Metastatic) 영역에서 개발·상용화 중입니다. 작용기전: checkpoint co-expression score correlated with both overall and contact-dependent tumor cell death. Phase 2에서 효능·안전성 신호를 검증 중입니다. OS: 16. 차별점: novel treatment approach aiming to increase precision and reduce toxicity compared with traditional immune checkpoint inhibit.
구조화 카탈로그 레코드입니다. Curated Core만큼 깊게 검토되지 않았습니다.
구조화 데이터
Lung Cancer (Locally Advanced or Metasta
Lung Cancer (Locally Advanced or Metastatic); Liver Cancer (Locally Advanced or Metastatic)
Recruiting
2026-07-13
Data Confidence · Medium
Development Signal · Emerging
NK cell activation in MDOTS when combined with TGFβ and PD-1
Lentiviral vectors encoding murine or human IL6/1 were designed using Vector Builder and e
novel treatment approach aiming to increase precision and reduce toxicity compared with traditional immune checkpoint inhibit
checkpoint co-expression score correlated with both overall and contact-dependent tumor cell death
T-cell activation
apoptosis through soluble inflammatory mediators in a same-donor primary-cell system
biomarkers and therapeutic targets for investigating tumor-specific immune responses following locoregional t
downregulation of inflammation-related pathways, whereas another allogeneic donor strain induced a distinct transcriptional profile
구조화 데이터
rates anti-tumor activity in human melanoma xenograft
mouse
PD
구조화 데이터
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.
바이오정보모아는 연구·교육용 과학·의약품 개발 정보입니다. 진료, 진단, 치료 지침, 규제 자문이 아닙니다.